Breast Cancer

, Volume 8, Issue 2, pp 131–137 | Cite as

Evaluation of bone metabolic markers in breast cancer with bone metastasis

  • Noriaki Wada
  • Masato Fujisaki
  • Seiichiro Ishii
  • Tadashi Ikeda
  • Masaki Kitajima
Original Article



In the present study, four bone metabolic markers were examined to clarify them meaning and clinical value in the detection of bone metastasis (BM) from breast cancer.


we examined serum carboxyterminal telopeptide of type I collagen (ICTP), tartrate resistant acid phosphatase (TRACP), total alkaline phosphatase (ALP) and urinary type I collagen cross-linked N-telopeptides (NTx) as potential markers. These bone markers were evaluated simultaneously in 156 breast cancer patients; 114 patients without metastasis (group A), 23 patients with BM (group B) and 19 patients with metastasis at sites other than bone (group C).


The mean values of ICTP and TRACP in group B were significantly greater than those in group A. Group B consisted of the patients with varying degrees of BM and variation in their treatments. The patients in group B were divided into BM (+) and BM (++) according to hot spots in bone scan. ICTP and TRACP were elevated in BM (++) patients compared to BM (+) patients (p<0.05). The values of ICTP and TRACP of the twelve patients without treatment in group B were significantly higher than those in group A. In the treated patients of group B, the mean values of ICTP and TRACP were lower in responders and cases of stable disease than those with progression. NTx and ALP were inferior to ICTP and TRACP for clinical evaluation of BM.


We confirmed that ICTP and TRACP might be useful markers for screening and monitoring BM in breast cancer.

Key words

Breast cancer Bone metastasis Bone metabolic marker Tartrate resistant acid phosphatase Carboxyterminal telopeptide of type I collagen 



Bone metastasis


Carboxyterminal telopeptide of type I collagen


Tartrate resistant acid phosphatase


Total alkaline phosphatase


Urinary type I collagen cross-linked N-telopeptiaes


First recurrence in the form of bone metastasis


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    Coleman RE, Rubens RD: The clinical course of bone metastases from breast cancer.Br J Cancer 55:61–66, 1987.PubMedGoogle Scholar
  2. 2).
    Osawa S, Iida S, Yonemitsu H,et al: Prostatic acid phosphatase assay with self-indicating substrate 2, 6- dichloro-4-acetylphenyl phosphate.Clin Chem 41:200–203, 1995.PubMedGoogle Scholar
  3. 3).
    Risteli J, Elomaa I, Niemi S,et al: Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation.Clin Chem 39:635–640, 1993.PubMedGoogle Scholar
  4. 4).
    Hanson DA, Weis MAE, Bollen AM,et al: A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopep- tides in urine.J Bone Miner Res 7:1251–1258, 1992.PubMedGoogle Scholar
  5. 5).
    Eyre D: New biomarkers of bone resorption.J Clin Endocrinol Metabo 74:470A-470C, 1992.CrossRefGoogle Scholar
  6. 6).
    The Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer, 13th ed., Kanehara Co, Tokyo, 1998.Google Scholar
  7. 7).
    Desoize B, Delvincourt C, Comoe L: Comparison of 4 techniques of Alkaline phosphatase isoenzyme assay.Clin Chem Enzymol Commun 2:107–114, 1990.Google Scholar
  8. 8).
    Minkin C: Bone acid phosphatase: Tartrate-resistant acid phosphatase as a marker of osteoclast function.Calcif Tissue Int 34:285–290, 1982.PubMedCrossRefGoogle Scholar
  9. 9).
    Stepan JJ, Zichova M, Lachmanova J,et al: Plasma tartrate resistant acid phosphatase: a marker for osteo- clastic bone resorption.Acta Univ Carol Med Praha 32:345–353, 1986.PubMedGoogle Scholar
  10. 10).
    Chambers TJ, Fuller K, Darby JA: Hormonal regula- tion of acid phosphatase release by osteoclasts disaggregated from neonatal rat bone.J Cell Physiol 132:90–96, 1987.PubMedCrossRefGoogle Scholar
  11. ll).
    Mundy GR, Ibbotson KJ, D’Souza SM: Tumor products and the hypercalcemia of malignancy.J Clin Invest 76:391–419, 1985.PubMedCrossRefGoogle Scholar
  12. 12).
    Chen J, Yam LT, Janckila AJ,et al: Significance of “high” acid phosphatase activity in the serum of normal chil- dren.Clin Chem 25:719–722, 1979.PubMedGoogle Scholar
  13. 13).
    de la Piedra C, Torres R, Rapado A,et al: Serum tartrate-resistant acid phosphatase and bone mineral content in postmenopausal osteoporosis.Calcif Tissue Int 45:58–60, 1989.PubMedCrossRefGoogle Scholar
  14. 14).
    Lau KH, Onishi T, Wergedal JE,et al: Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption.Clin Chem 33:458–462, 1987.PubMedGoogle Scholar
  15. 15).
    Stepan JJ, Silinkova Malkova E, Havranek T,et al: Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism.Clin Chim Acta 133:189–200, 1983.PubMedCrossRefGoogle Scholar
  16. 16).
    Cheung CK, Panesar NS, Haines C,et al: Immunoassay of a tartrate-resistant acid phosphatase in serum [see comments].Clin Chem 41:679–686, 1995.PubMedGoogle Scholar
  17. 17).
    Kraenzlin M: Development of immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase.J Clin Endocrinol Metab 71:442451, 1990.CrossRefGoogle Scholar
  18. 18).
    Eriksen EF, Charles P, Melsen F,et al: Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphome- try.J Bone Miner Res 8:127–132, 1993.PubMedCrossRefGoogle Scholar
  19. 19).
    Risteli J, Elomaa I, Niemi S,et al: Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation.Clin Chem 39:635–640, 1993.PubMedGoogle Scholar
  20. 20).
    Wada N, Ishii S, Ikeda T,et al: Serum tartrate resistant acid phosphatase as a potential marker of bone metasta- sis from breast cancer.Anticancer Res 19:4515–4522, 1999.PubMedGoogle Scholar
  21. 21).
    Koizumi M, Takahashi S, Ogata E: Bone metabolic markers in bone metastasis of breast cancer.Int J Clin Oncol 4:331–337, 1999.CrossRefGoogle Scholar
  22. 22).
    Shimozuma K, Sonoo H, Fukunaga M,et al: Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report.Jpn J Clin Oncol 29:16–22, 1999.PubMedCrossRefGoogle Scholar
  23. 23).
    Koizumi M, Matsumoto S, Takahashi S,et al: Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer.Clin Nucl Med 24:15–20, 1999.PubMedCrossRefGoogle Scholar
  24. 24).
    Demers LM, Costa L, Chinchilli VM,et al: Biochemical markers of bone turnover in patients with metastatic bone disease.Clin Chem 41:1489–1494, 1995.PubMedGoogle Scholar
  25. 25).
    Bombardieri E, Martinetti A, Miceli R,et al: Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer.Eur J Nucl Med 24:1349–1355, 1997.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2001

Authors and Affiliations

  • Noriaki Wada
    • 1
    • 3
  • Masato Fujisaki
    • 1
  • Seiichiro Ishii
    • 2
  • Tadashi Ikeda
    • 3
  • Masaki Kitajima
    • 3
  1. 1.Department of SurgeryAshikaga Red Cross HospitalJapan
  2. 2.Department of SurgeryKawasaki City HospitalJapan
  3. 3.Department of SurgeryKeio University School of MedicineJapan

Personalised recommendations